Your session is about to expire
← Back to Search
Behavioral Health Intervention for Developmental Disabilities (BEST Trial)
N/A
Waitlist Available
Led By Kristin L Berg, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a combined mental health treatment and care coordination program for youth with disabilities to see if it helps them cope better with anxiety, depression, and manage their health better. 780 youth in Illinois will be randomly placed in either the combined program or care coordination alone.
Who is the study for?
This trial is for young people aged 13-20 with intellectual and/or developmental disabilities (IDD) who are enrolled in MCHB care in Illinois. They must be able to consent to the study and have at least a 4th-grade reading level. Those with severe intellectual disability (IQ <50) or very low comprehension skills are not eligible.
What is being tested?
The BEST Study tests if adding mental health treatment to MCHB care coordination helps youth with IDD feel less anxious and depressed, healthier, function better, practice healthy habits, and manage their health more effectively compared to standard MCHB care coordination.
What are the potential side effects?
Since this trial involves behavioral interventions like online programs and group meetings rather than medication, traditional side effects aren't expected. However, discussing sensitive topics could potentially cause temporary discomfort or emotional distress.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Anxiety Symptomatology
Anxiety Symptomatology of Caregiver
Depressive Symptomatology
+3 moreSecondary study objectives
Adverse Childhood Experiences
Caregiver-Reported Adaptive Functioning
Cognitive Style
+17 moreOther study objectives
Sociodemographic Information
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Illinois MCHB Care Coordination + CHECK tiered behavioral healthExperimental Treatment6 Interventions
MCHB Care Coordination plus CHECK: includes all elements of MCHB care coordination, described above, plus the CHECK program. The CHECK program consists of a trained, behavioral health care team; an evidence-based treatment algorithm to classify risk for depression and anxiety (minimal, subclinical and clinical symptomatology) and guide treatment advancement \[Tier 1/selective: cognitive behavioral psycho-education; Tier 2/indicated: cognitive-behavioral prevention groups; Tier 3/treatment: individualized or group cognitive-behavioral treatment (CBT)\]; as well as structures and processes to support communication, coordination and data sharing between MCHB care coordinators and CHECK staff.
Group II: Illinois MCHB Care CoordinationActive Control1 Intervention
MCHB Care Coordination is funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, this is the oldest and most universal care coordination model for children with I/DD. The University of Illinois Chicago Division of Specialized Care for Children (DSCC) is the Illinois (IL) state Title V MCHB care coordination agency and has annual contact with over 19,000 families and youth in IL. MCHB (known as DSCC) Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
Find a Location
Who is running the clinical trial?
University of Illinois at ChicagoLead Sponsor
640 Previous Clinical Trials
1,567,928 Total Patients Enrolled
29 Trials studying Depression
6,715 Patients Enrolled for Depression
Wellesley CollegeOTHER
5 Previous Clinical Trials
2,370 Total Patients Enrolled
4 Trials studying Depression
2,270 Patients Enrolled for Depression
The Arc of IllinoisUNKNOWN
University of ChicagoOTHER
1,062 Previous Clinical Trials
839,354 Total Patients Enrolled
19 Trials studying Depression
10,507 Patients Enrolled for Depression
University of California, Los AngelesOTHER
1,569 Previous Clinical Trials
10,313,509 Total Patients Enrolled
106 Trials studying Depression
48,772 Patients Enrolled for Depression
Kristin L Berg, PhDPrincipal InvestigatorUniversity of Illinois at Chicago
Benjamin W Van Voorhees, MD, MPHPrincipal InvestigatorUniversity of Illinois at Chicago
2 Previous Clinical Trials
1,064 Total Patients Enrolled
2 Trials studying Depression
1,064 Patients Enrolled for Depression
Iulia Mihaila, PhDStudy DirectorUniversity of Illinois at Chicago
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am unable to give consent for the study as per the MacCAT-CR assessment.I have a severe intellectual disability (IQ below 50).I am between 13 and 20 years old with an intellectual or developmental disability, receiving care through IL DSCC.
Research Study Groups:
This trial has the following groups:- Group 1: Illinois MCHB Care Coordination + CHECK tiered behavioral health
- Group 2: Illinois MCHB Care Coordination
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.